TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33065702

Group type: EXPERIMENTAL
Intervention: Compression socks
Number of subjects: 46

Group type: COMPARATOR
Intervention: No compression socks (control)
Number of subjects: 46
Study: 34295782

Group type: EXPERIMENTAL
Intervention: Bifidobacterium triple viable
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study: 32826122

Group type: EXPERIMENTAL
Intervention: POCUS
Number of subjects: 162
Study: 36396306

Group type: EXPERIMENTAL
Intervention: RCyBorD(x4) induction therapy followed by high-dose melphalan and ASCT, with 12 cycles of Isa maintenance for MRD-negative patients.
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: R, RBorD(x4) + R, RIsa, or RBorIsaD(x4) + RIsa for MRD-positive patients.
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: RBorD(x4) + R or RBorIsaD(x4) + RIsa for high-risk patients.
Number of subjects: 1400
Study: 34103179

Group type: EXPERIMENTAL
Intervention: docetaxel (75 mg/m2)
Number of subjects: 188

Group type: COMPARATOR
Intervention: cabazitaxel (20 or 25 mg/m2)
Number of subjects: 188

Group type: COMPARATOR
Intervention: cabazitaxel (20 or 25 mg/m2) in PROSELICA
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: plasma lpWGS of ctDNA
Number of subjects: 188
Study: 33320753

Group type: EXPERIMENTAL
Intervention: Hydrocolloid/hydrogel dressings plus 20 exposures to low-level laser therapy (LLLT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hydrocolloid dressings alone
Number of subjects: 43
Study: 35143744

Group type: EXPERIMENTAL
Intervention: Continue RAASi
Number of subjects: 46

Group type: COMPARATOR
Intervention: Discontinue RAASi
Number of subjects: 46
Study: 34255369

Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine (ADH)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir/Hydroxychloroquine (KH)
Number of subjects: 62
Study: 32807079

Group type: EXPERIMENTAL
Intervention: Folded replication slippage model
Number of subjects: 55

Group type: COMPARATOR
Intervention: Existing straight-line slippage model
Number of subjects: 55
Study: 35421224

Group type: EXPERIMENTAL
Intervention: Gain version of the BART (pumping the balloon added monetary gains)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Loss version of the BART (pumping the balloon avoided monetary losses)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Total performance on the BART
Number of subjects: 254
Study: 36057576

Group type: EXPERIMENTAL
Intervention: Combined model based on radiomics features of Gd-EOB-DTPA enhanced MRI, tumour margin, and peritumoural hypointensity
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clinicoradiological model
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Nomogram model based on the combined model
Number of subjects: 165
Study: 34521670

Group type: EXPERIMENTAL
Intervention: Mobile case management application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual case management practices
Number of subjects: 0
Study: 36053806

Group type: EXPERIMENTAL
Intervention: Molnupiravir 1600 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg every 12 hours for 5.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg every 12 hours for 5.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg and 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration with food
Number of subjects: 0
Study: 34290036

Group type: EXPERIMENTAL
Intervention: Tablet-delivered CV educational videos and CPR video
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Tablet-delivered CV educational videos
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: CPR video
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Baseline to 30-day follow-up CV RFs
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study: 36418441

Group type: EXPERIMENTAL
Intervention: Music training (piano training)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Music listening
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (doing homework)
Number of subjects: 31
Study: 32047237

Group type: EXPERIMENTAL
Intervention: TCD-haplo + ATIR101
Number of subjects: 23

Group type: COMPARATOR
Intervention: TCD-haplo alone
Number of subjects: 23

Group type: COMPARATOR
Intervention: MMUD
Number of subjects: 23

Group type: COMPARATOR
Intervention: MUD
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ATIR101 grafts with high third-party reactivity
Number of subjects: 23
Study: 34999928

Group type: EXPERIMENTAL
Intervention: Ex-diet (n-6 PUFA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: C-diet (Control)
Number of subjects: 99
Study: 32359044

Group type: EXPERIMENTAL
Intervention: Group behavioral couples' therapy plus individual‐based treatment (G‐BCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard behavioral couples' therapy plus individual‐based treatment (S‐BCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Incremental cost-effectiveness ratios (ICER) moving from G‐BCT to S‐BCT
Number of subjects: 101

Group type: COMPARATOR
Intervention: Percentage days abstinent, adverse consequences of alcohol and drugs, overall relationship functioning
Number of subjects: 101
Study: 34998419

Group type: EXPERIMENTAL
Intervention: FKB327
Number of subjects: 260

Group type: COMPARATOR
Intervention: Adalimumab RP
Number of subjects: 260
Study: 35676457

Group type: EXPERIMENTAL
Intervention: LSDL (Laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: LSDL
Number of subjects: 88

Group type: COMPARATOR
Intervention: LSD (Laparoscopic splenectomy and azygoportal disconnection)
Number of subjects: 88
Study: 33851461

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (2 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 60
Study: 32780356

Group type: EXPERIMENTAL
Intervention: EBNA1-IgA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: EBV DNA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: VCA-IgA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: EA-IgA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rta-IgG
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Zta-IgA
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 106
Study: 33497362

Group type: EXPERIMENTAL
Intervention: Anti-CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine
Number of subjects: 22
Study: 33625518

Group type: EXPERIMENTAL
Intervention: Topical Timolol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 34437553

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (various attributes assessed)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Food-drug interaction concern
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Frequency of blood monitoring
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Educational attainment and income level impact
Number of subjects: 506
Study: 32511774

Group type: EXPERIMENTAL
Intervention: Liberalized dietary sodium intake (200 mmol/d, 4600 mg/d)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Restricted dietary sodium intake (10 mmol/d, 230 mg/d)
Number of subjects: 630
Study: 34338327

Group type: EXPERIMENTAL
Intervention: Mendelian randomization using genetic variants as instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-sample conditional F-statistic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterogeneity Q-statistic
Number of subjects: 0
Study: 36343090

Group type: EXPERIMENTAL
Intervention: NERD stagnated heat in liver and stomach syndrome group
Number of subjects: 60

Group type: COMPARATOR
Intervention: qi stagnation and phlegm obstruction syndrome control group
Number of subjects: 60

Group type: COMPARATOR
Intervention: normal control group
Number of subjects: 60
Study: 35192610

Group type: EXPERIMENTAL
Intervention: hsCRP 2.0 to 4.9 mg/L
Number of subjects: 102337

Group type: EXPERIMENTAL
Intervention: hsCRP 5 to 9.9 mg/L
Number of subjects: 102337

Group type: EXPERIMENTAL
Intervention: hsCRP 10 to 15 mg/L
Number of subjects: 102337

Group type: COMPARATOR
Intervention: hsCRP <2 mg/L
Number of subjects: 102337
Study: 34287833

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 20 mg/kg/day, titrated up to 30 mg/kg/day over 2 weeks
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment
Number of subjects: 366
Study: 32846328

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 22678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22678
Study: 36342337

Group type: EXPERIMENTAL
Intervention: Educational intervention about health, medication use, and communication strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional services (control group)
Number of subjects: 0
Study: 33561565

Group type: EXPERIMENTAL
Intervention: Incentive-based interventions
Number of subjects: 9
Study: 32540210

Group type: EXPERIMENTAL
Intervention: Mandatory accreditation (non-monetary incentive)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Perception of accreditation as a tool for external control
Number of subjects: 846
Study: 32859731

Group type: EXPERIMENTAL
Intervention: Ketamine-Propofol (KP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sodium Thiopental-Fentanyl (TF)
Number of subjects: 96
Study: 34928708

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1125
Study: 32077768

Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 87
Study: 36146287

Group type: EXPERIMENTAL
Intervention: Real-time wearable feedback with daily goal using the Manumeter device for three weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group using the Manumeter as a wristwatch without real-time feedback for three weeks
Number of subjects: 20
Study: 33226425

Group type: EXPERIMENTAL
Intervention: 900 mg/d ezogabine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 600 mg/d ezogabine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 35090543

Group type: EXPERIMENTAL
Intervention: Blood-flow restriction training (BFRT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham BFRT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Standard of care physical therapy
Number of subjects: 78
Study: 34137474

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss (BWL)
Number of subjects: 90
Study: 32799922

Group type: EXPERIMENTAL
Intervention: High‐intensity speed‐based treadmill training (HISTT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: tDCS+AMT (15 min of concurrent tDCS and ankle motor tracking)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: tDCS (15 min of stimulation‐based priming)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (15 min of rest)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ankle motor tracking (AMT) with sham tDCS (15 min of movement‐based priming)
Number of subjects: 81
Study: 36817806

Group type: EXPERIMENTAL
Intervention: Supportive training program including teaching parental roles and supportive methods, nurse counseling and support role performed virtually
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study: 32482668

Group type: EXPERIMENTAL
Intervention: Tailored therapeutic exercise protocol followed by a cryotherapy session of 20 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control group receiving the same regimen as the experimental group but with sham packs filled with dry sand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active treatment control group receiving only the therapeutic exercise protocol
Number of subjects: 0
Study: 35534916

Group type: EXPERIMENTAL
Intervention: G‐6‐PD‐deficient RBCs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal RBCs
Number of subjects: 24
Study: 32223002

Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride 4% with epinephrine 1:100,000
Number of subjects: 184

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride 2% with epinephrine 1:100,000
Number of subjects: 184
Study: 36305963

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing B. lactis HN019
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 60
Study: 34274619

Group type: EXPERIMENTAL
Intervention: Telehealth followup with wearable sensors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional face to face visits with symptom diaries
Number of subjects: 0
Study: 35830578

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 48

Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 48
Study: 34736563

Group type: EXPERIMENTAL
Intervention: FFR-guided treatment strategy
Number of subjects: 927

Group type: COMPARATOR
Intervention: Traditional strategy without FFR (Control)
Number of subjects: 927
Study: 34756733

Group type: EXPERIMENTAL
Intervention: 3D miniplate osteosynthesis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Two Champy's miniplates
Number of subjects: 2
Study: 34748679

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 82
Study: 33515070

Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg with dose escalation to 67.5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral insulin (in children with the type 1 diabetes‐susceptible INS genotype)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (in children with the type 1 diabetes‐susceptible INS genotype)
Number of subjects: 44
Study: 35064428

Group type: EXPERIMENTAL
Intervention: Vermont Family Based Approach (health promotion program)
Number of subjects: 93
Study: 33620895

Group type: EXPERIMENTAL
Intervention: 100 U onabotulinumtoxinA
Number of subjects: 307

Group type: COMPARATOR
Intervention: 200 U onabotulinumtoxinA
Number of subjects: 307
Study: 32778150

Group type: EXPERIMENTAL
Intervention: Cys/Metlow + PUFA (meal low in sulfur amino acids and high in polyunsaturated fatty acids)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cys/Methigh + SFA (meal high in sulfur amino acids and saturated fatty acids)
Number of subjects: 10
Study: 36273202

Group type: EXPERIMENTAL
Intervention: Nalbuphine 80 mg + 0.9% normal saline (72 ml) in patient-controlled analgesia pump
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 80 mg
Number of subjects: 0
Study: 32736963

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 30 breaths at 30–40% of PImax, 5 days a week for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 35193608

Group type: EXPERIMENTAL
Intervention: SMC combined with RTS,S/AS01E
Number of subjects: 5920

Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 5920

Group type: COMPARATOR
Intervention: RTS,S/AS01E alone
Number of subjects: 5920
Study: 34903244

Group type: EXPERIMENTAL
Intervention: Cryotherapy using CryoPop®
Number of subjects: 0
Study: 35816723

Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 16
Study: 33911153

Group type: EXPERIMENTAL
Intervention: Barbell resistance exercise (75% 1RM, 5 repetitions, 3 sets, 2-3 min rest)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Barbell resistance exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active control (stretching exercise session)
Number of subjects: 24
Study: 36482412

Group type: EXPERIMENTAL
Intervention: lecanemab (ED90)
Number of subjects: 856
Study: 33992277

Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: General exercise group (GEG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Educational group (EG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 46
Study: 33167921

Group type: EXPERIMENTAL
Intervention: Activity-oriented proprioceptive antiedema therapy (TAPA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional treatments (Decongestive Lymphedema Therapy (DLT) or Complex Physical Therapy (CPT))
Number of subjects: 64
Study: 34649730

Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation plus Total Hip Arthroplasty (ORIF + THA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open Reduction and Internal Fixation (ORIF) alone
Number of subjects: 47
Study: 32633571

Group type: EXPERIMENTAL
Intervention: Version 1 (coercive tactic first)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Version 2 (sexual acts first)
Number of subjects: 1253
Study: 35101539

Group type: EXPERIMENTAL
Intervention: KCCQ‐23 Overall Summary Score (OSS)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: KCCQ‐23 Clinical Summary Score
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: EQ5D‐VAS
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: NYHA class
Number of subjects: 631
Study: 33264825

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study: 32840417

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2 once every 3 weeks (≤ 6 cycles)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pazopanib and Doxorubicin
Number of subjects: 120
Study: 35120566

Group type: EXPERIMENTAL
Intervention: Minocycline 50 mg orally, followed by 50 mg once a day for 5 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo with the same schedule as minocycline
Number of subjects: 73
Study: 33429278

Group type: EXPERIMENTAL
Intervention: Justa stove
Number of subjects: 230

Group type: COMPARATOR
Intervention: Traditional stove
Number of subjects: 230
Study: 36052134

Group type: EXPERIMENTAL
Intervention: SanHanHuaShi granules
Number of subjects: 240

Group type: COMPARATOR
Intervention: LianHuaQingWen granules
Number of subjects: 240
Study: 32493468

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon‐β 1a (Recigen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon‐β 1b (Ziferon)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra)
Number of subjects: 60
Study: 34728529

Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 32133487

Group type: EXPERIMENTAL
Intervention: Oral doxycycline 100 mg twice daily for 4 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 2 g daily for 3 weeks
Number of subjects: 210
Study: 32242826

Group type: EXPERIMENTAL
Intervention: Content-tailored condition
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Message frame-tailoring
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Content-tailoring
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Message frame-tailoring and content-tailoring interaction
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Message frame-tailored for individuals with high need for autonomy + content-tailored messages
Number of subjects: 273
Study: 35377557

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behavioral Therapy (TCBT) during eight sessions provided by trained general health service providers
Number of subjects: 520

Group type: COMPARATOR
Intervention: Mental Health Services as Usual (MHSU)
Number of subjects: 520
Study: 35437030

Group type: EXPERIMENTAL
Intervention: Acupuncture (12 treatment sessions over 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture (12 treatment sessions over 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 32641335

Group type: EXPERIMENTAL
Intervention: New ultrafiltration (UF) profile with an ascending/descending shape and standard dialysate sodium concentration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of different UF and sodium profiling strategies through individualised dialysate sodium concentration
Number of subjects: 27
Study: 35400288

Group type: EXPERIMENTAL
Intervention: Picosecond 532 nm laser (PS 532)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Q-switched 755 nm Alexandrite laser (QSAL)
Number of subjects: 18
Study: 32588968

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR with third generation THV systems (Edwards Sapien3®/Sapien3ultra® or Medtronic Evolut‐R®/Evolut‐PRO®) using PerClose‐ProGlide® vascular closure device
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Sheath-to-femoral-artery-ratio (SFAR) increase
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: More than 2 vessel entries with large bore sheaths
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Two vessel entries with large bore sheaths
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Vessel wall calcification at puncture site
Number of subjects: 878
Study: 33374694

Group type: EXPERIMENTAL
Intervention: Sea salt-based mouthwash containing xylitol and lysozyme
Number of subjects: 0
Study: 34224342

Group type: EXPERIMENTAL
Intervention: Low-impact dance intervention (LG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0